Albert David Ltd Stock Analysis

BSE: 524075 | NSE: ALBERTDAVD | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 23-Sep-2022 18:01
565.00 -0.30 (-0.05%)

DeciZen - Make an Informed Decision on Albert David

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Albert David Price Chart

P/E Ratio (SA) :
12.14
Market Cap :
322.5 Cr.
52-wk low :
485.4
52-wk high :
738.4
Bole Toh?

1. Is Albert David Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Albert David Ltd is a average quality company.

2. Is Albert David Ltd undervalued or overvalued?

The key valuation ratios of Albert David Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Albert David Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Albert David Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Albert David:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Albert David Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 9.1%12%11.9%14.6%7.7%3.4%7.3%9.9%9.2%12.5%-
Value Creation Index -0.4-0.1-0.20.0-0.5-0.8-0.5-0.3-0.3-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 265291322323295290317321247314326
YoY Gr. Rt. %-9.7%10.7%0.3%-8.5%-1.7%9.3%1.1%-22.9%26.7%-
Adj EPS 14.421.72333.323.711.42636.43757.146.6
YoY Gr. Rt. %-50.8%6%44.5%-28.8%-52%128.7%39.8%1.6%54.4%-
BVPS (₹) 142.1158.3162.6239.8320.7325.8368.7390.4428.2489.7492.8
Adj Net Profit 8.212.413.21913.56.514.920.821.132.627
Cash Flow from Ops. 20.220.827.86819.93031.930.336.640.4-
Debt/CF from Ops. 1.921.10.31.50.900.100.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 1.9%1.2%-0.4%26.7%
Adj EPS 16.5%19.2%29.9%54.4%
BVPS 14.78.89.914.4
Share Price 16.9% 14.4% 15.3% -4.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 10.514.514.416.68.53.57.59.6912.49.5
Op. Profit Mgn % 1011.311.59.76.65.99.410.67.813.113.1
Net Profit Mgn % 3.14.34.15.94.62.24.76.58.510.48.2
Debt to Equity 0.50.50.30.20.20.20000-
Working Cap Days 1431601741611942121931902271830
Cash Conv. Cycle 454960626247322836260

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 29.93%

Sales growth is good in last 4 quarters at 19.06%

Return on Equity has declined versus last 3 years average to 9.50%

Sales growth has been subdued in last 3 years -0.39%

Latest Financials - Albert David Ltd.

Standalone Consolidated
TTM EPS (₹) 46.6 -
TTM Sales (₹ Cr.) 326 -
BVPS (₹.) 492.8 -
Reserves (₹ Cr.) 276 -
P/BV 1.15 -
PE 12.14 -
From the Market
52 Week Low / High (₹) 485.40 / 738.40
All Time Low / High (₹) 3.15 / 854.75
Market Cap (₹ Cr.) 322
Equity (₹ Cr.) 5.7
Face Value (₹) 10
Industry PE 37.9

Management X-Ray of Albert David :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Albert David

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

About Albert David Ltd

Albert David was incorporated in the year 1938. The company is a part of Kothari group.

Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier.

It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator.

The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.

The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress.

ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India.

Products offered by the Company:

The company is operating in major therapeutic segments that include:

  • Analgesics/AntiInflammatory
  • Anti-Bacterials
  •  Anti-Ulcerants
  •  Dermatologicals
  • Anxiolytics
  • Large Volume Parenteral
  •  Disposable Syringes & Needles
  • Herbal Drugs
  • Nutrition
  • Neurotropics
  •  Placental Extracts
  •  Anthelmintic
  • Haemostati
  • Cough Preparations
  • Laxatives
  • Skeletal Relaxants
  • Anti-Arthiritic / Chondroprotective Agents.

Future Plans:

  • The company will explore the possibilities for export of its IV fluids, small volume parenterals and disposable syringes in addition to its existing range.
  • It will concentrate on product line extension for its flagship brand Placentrex by bringing in newer formulations and looking for a new therapeutic area of usage.
  •  Future expansion in the herbal product range will be focused in the area of women`s healthcare.
  • ADL is planning to enter newer therapeutic areas like dermatological and ophthalmological segments.
  • Furthermore, it will also strengthen its presence in the gastrointestinal segments and in the areas of pain management.
  •  The company is also planning to launch newer products in the areas of nutritional, gynaecological and herbal medicine.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now